Immune control of Epstein-Barr virus in MS

Progress to Date

Professor Pender has been able to show that the deficiency in CD8 T cells in people with MS is specifically due to reduced numbers of a sub-group of CD8 T cells called CD8 effector memory T cells. These cell types retain a memory of pathogens that they have ‘seen’ before and can immediately mount a response to clear infected cells.

Professor Pender has also examined blood samples from a large number of people with all forms of MS including the earliest signs of MS, known as Clinically Isolated Syndrome (CIS). The CD8 effector memory cell deficiency is present in all of these stages and types of the disease, including the very earliest stage, CIS, suggesting that is a cause, rather than a consequence, of the disease. He has also shown that other T cell types are also decreased over the course of disease, contributing to overall T cell exhaustion.

Professor Pender will continue to tease apart the mechanism by which this deficiency may lead to inadequate control of EBV infection, and how this may lead to MS. Professor Pender will also look at the relationship between MS and different phases of EBV infection as well as the immune response to EBV infection.

This work is vitally important for the development of new therapies aimed at preventing and treating MS by controlling EBV infection. An exciting development in this direction was revealed earlier this year, when Professor Pender and his colleagues published the promising results for a patient with secondary progressive MS who was treated with CD8 cells primed to recognise EBV. The therapy had no adverse effects and the patient showed clinical improvement with reduced disease activity. This is the first time that this type of therapy, known as adoptive immunotherapy, has been used to treat MS or any other autoimmune disease. Professor Pender and colleagues are now planning to undertake a phase I clinical trial of the therapy.